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Objective Over the past decade, there has been an 
increase in reports of health research from Palestine, but 
no assessment of their quality. We have assessed the 
quality of reports of Palestinian health research and factors 
associated with it.
Design This is a systematic review.
Inclusion criteria We searched Medline and Scopus 
for reports of original research relevant to human health 
or healthcare authored by researchers affiliated with 
Palestinian institutions and published between January 
2000 and August 2015 inclusive.
Outcomes We used international guidelines to assess 
report quality, classifying as adequate those with ≥50% of 
items completely addressed.
Results Of 2383 reports identified, 497 met our inclusion 
criteria. Just over half (264; 55%) of these were published 
after 2010. 354 (71%) of first authors were affiliated with 
Palestinian institutions; 261 (53%) reports had coauthors 
from outside Palestine. The majority of the reports in our 
study were inadequately reported (342; 69%), and none 
had adequately reported all items. Of 439 observational 
studies, 11 (2.5%) reports provided adequate descriptions 
of eligibility criteria and selection procedures; 35 (8%) 
reported efforts to address potential sources of bias; 50 
(11.4%) reported the basis for the study sample size; and 
funding sources were mentioned in 74 reports (17%). 
Higher reporting quality was associated with international 
affiliation of the first author (prevalence ratio (PR) 1.6 (95% 
CI 1.2 to 2.1)), international collaboration (PR 2.9 (95% CI 
1.7 to 5.0)), international funding (PR 1.9 (95% CI1.5 to 
2.5)), publication after 2005 (PR 3.9 (95% CI 1.8 to 8.5)) 
and four or more coauthors (PR 1.5 (95% CI 1.1 to 2.1)).
Conclusion Although the quality of reports of Palestinian 
research has improved in recent years, it remains well 
below an acceptable standard. International reporting 
guidelines should be used to guide research design and 
improve the quality of reports of research.
Trial registration number The systematic review protocol 
was registered in the International Prospective Register 
of Systematic Reviews (PROSPERO) registery (registration 
number: CRD42015027553).
IntroductIon
Research reports are the most common way 
to communicate research findings for target 
readerships. Complete, accurate and trans-
parent reporting of research studies facilitates 
dissemination, interpretation, translation 
and replication of research findings.1 Inad-
equate reporting has major consequences 
for clinicians, researchers, policy makers 
and ultimately patients.2 It impairs critical 
assessment of the validity, relevance and trust-
worthiness of research and so impedes its use 
in practice.3 It also limits the usability of study 
findings by other researchers conducting 
systematic reviews and meta-analyses and 
building on or replicating studies.4 In addi-
tion, inadequate reporting is one of the key 
contributors to avoidable waste in biomedical 
research.5 6 Researchers thus have an ethical 
obligation to research participants, funding 
organisations and society as a whole to report 
their findings in ways that are of use in prac-
tice and policymaking.
Several guidelines have been devel-
oped in attempts to improve the quality of 
the reporting of research. These include 
CONsolidated Standards of Reporting Trials 
(CONSORT),7 STrenghtening the Reporting 
of Observational studies in Epidemiology 
(STROBE),8 Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses 
(PRISMA),9 Standards for Reporting of Diag-
nostic Accuracy (STARD),10 CAse REports 
(CARE)11 and Transparent Reporting of a 
multivariable prediction model for Individual 
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Research
Strengths and limitations of this study
 ► This is the first study to examine the quality of 
reporting of health research in Palestine or in 
any Arab country, using international reporting 
guidelines.
 ► Citation screening and data extraction were 
conducted by two independent authors in duplicate.
 ► We used internationally developed criteria from the 
Enhancing the QUAlity and Transparency Of health 
Research (EQUATOR) Network.
 ► We only searched two databases—Medline and 
Scopus—and that is only up to 2015 so we may 
have missed eligible studies not covered by these 
databases.
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Prognosis Or Diagnosis (TRIPOD).12 Evidence suggests 
that the adoption of these guidelines improves the quality 
of reporting of health research13–15 and the process and 
support of reviewers preparing quality reviews.16
Palestinian medical and public health institutions are 
relatively young and face many challenges, including 
scarce financial resources and limited research infrastruc-
ture. However, research is incentivised and encouraged 
at an institutional level and is linked to academic promo-
tion.17 Furthermore, Palestinian academics, like those 
elsewhere, work in an atmosphere in which the maxim 
‘publish or perish’ is accepted and promoted. As a result, 
researchers feel compelled to conduct research that they 
are often ill equipped to perform, with the consequence 
that it is done on too small a scale, over too short a time 
scale, and is subject to many possible biases.17
Health research in Palestine has been conducted 
initially in response to Palestinian community’s need to 
generate the evidence required to develop independent 
and informed health policies, with most of the resulting 
research studies ending up as unpublished reports.18 19 
Later, publication of research reports increased and a 
recent analysis shows that there has been a promising rise 
in medical and health publications from Palestine over 
the previous decade.17 However, the quality of these 
studies has only been assessed using bibliometric analysis 
(such as journal citation data), which is an inadequate 
measure of the quality of research. In this study, we have 
assessed the quality of reports of medical and health 
research reported by authors affiliated with Palestinian 
institutions and explored the factors associated with the 
better reporting.
Methods
study design
Systematic review: a protocol for this systematic review was 
devised in advance and registered in PROSPERO (regis-
tration no CRD42015027553). We followed PRISMA 
reporting guidance (see online supplementary material 
for PRISMA checklist).
search sources and strategy
We searched the Ovid Medline and Scopus databases 
for reports of Palestinian human medical and public 
health studies published between 2000 and 2015 inclu-
sive (search conducted on August 2015). We searched 
for the following terms in the author affiliation, title or 
abstract: ‘palestin*’, ‘jerusalem’, ‘west bank’, ‘gaza’, ‘oPt’, 
or ‘occupied Palestinian territories’ (for the complete 
search strategy, see online supplementary material).
eligibility criteria
We included any report of original research authored 
and/or coauthored by researchers affiliated with Pales-
tinian institutions. We included only research concerned 
with understanding anything that could have an effect 
on patients or other individuals and which had been 
conducted on individuals. We included quantitative 
studies, whether observational (cross-sectional, cohort, 
case–control studies and case series and reports), inter-
ventional (controlled trials) or systematic reviews and 
meta-analyses. Studies involving non-human animals were 
excluded. There were no language restrictions for inclu-
sion in this review.
study selection
Two reviewers (LA and MO) independently assessed 
the titles and abstracts of retrieved articles for definite 
or possible eligibility. We retrieved the full texts of all 
potentially eligible studies and assessed each full text 
independently by the same two reviewers. Disagreements 
about which studies to include were resolved by discus-
sion and consensus. Reasons for exclusion were identified 
and documented.
data extraction
For each included report, two reviewers (LA and MO 
independently used a data extraction form to record the 
following data: (1) citation details: authors, journal name, 
impact factor based on Journal Citation Report 2015,20 
number of citations and year of publication; (2) number 
of authors, the first author’s affiliation and any national, 
regional (ie, the Middle East North Africa (MENA) 
region) or international collaboration; (3) description of 
disease or health domain evaluated, based on the groups 
used to study global burden of disease21; (4) type of study 
question (aetiological, diagnostic, prognostic and inter-
ventional) and study design (randomised controlled trial 
(RCT), non-randomised intervention study, cohort, case–
control, cross-sectional and case report/series)22; and (5) 
source of funding (not reported/unclear, international/
non-governmental organisations (NGOs), local govern-
ment/or academic institution or industry).
Quality assessment of included studies
International Standard guidelines (STROBE,8 
CONSORT,7 PRISMA,9 CARE,11 TRIPOD12 and STARD10 
checklists) were used to assess the quality of reporting of 
each included study. We scored each item in each article 
as having been completely addressed (ie, when all the 
subitems were satisfactorily reported), partially addressed 
(ie, when some but not all the sub-items were satisfacto-
rily reported) or when none of them had been addressed. 
One author (LA) assessed the quality of reporting of all 
included studies. A random sample of 10% of all included 
studies was independently assessed by a second author 
(KE). The level of agreement between authors was esti-
mated using the kappa statistic (k=0.521; SE=0.033; 
95% CI=0.455–0.586; moderate agreement). We have not 
attempted to assess the methodological quality (risk of 
bias) of included studies.
reference to existing evidence
We also assessed whether the reports we included had 
referred to systematic reviews and/or meta-analyses of 
existing relevant research to justify the additional studies 
being reported, as recommended.23 Articles that have 
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cited, described or discussed (as defined by Helfer et al24) 
systematic reviews and/or meta-analysis were considered 
to have referred adequately to existing evidence.
data analyses and interpretation
We reported the proportion of reports that completely, 
partially or did not address each item in the relevant 
reporting guideline. We calculated the percentage 
of completely addressed items for each report and 
assessed the quality of reporting by the percentage of 
completely addressed items, deeming ‘adequate’ to be 
reports with ≥50% of items completely addressed and 
‘inadequate’<50%. We reported the total number and 
proportions of articles that completely reported ≥50% of 
the items, and then calculated the prevalence ratios (ie, 
the ratio of the proportion of the adequately reported 
studies with the examined factor over the proportion of 
the adequately reported studies without that factor, for 
example, publication year after 2005) comparing the 
following subgroups: author affiliation, collaboration, 
study question type, study design, funding source, number 
of authors per article, journal’s impact factor, number of 
citations and publication year). In addition, we reported 
mean±SD and the median and the IQR of the percentage 
of completely reported items per article for each subgroup. 
We used Fisher’s exact test (for categorical variables) and 
the Kruskal-Wallis test (for continuous variables) to inves-
tigate differences between groups.
results
Out of 2383 potentially relevant reports that we identified, 
we excluded 1591 based on screening titles and abstracts. 
Of the remaining 792 full-text reports, we included 497 in 
our study. The reasons for excluding the others were (i) 
none of the authors/coauthors was affiliated to a Pales-
tinian institution (105/295, 36%); (ii) it was a report 
of qualitative research (102/295, 35%); (iii) it had not 
been conducted on individual humans (eg, basic science 
research) (45/295, 15%); and (iv) full texts could not be 
retrieved (43/295; 14%) (figure 1).
characteristics of included studies
Publication details: just over half of the reports (265/497; 
53%) were published after 2010, a third (164/497; 33%) 
between 2005 and 2010 and only 68 (14%) before 2005. 
About a third of the reports were published in journals 
with no impact factor. The mean impact factor of journals 
those published in which some of our study popula-
tion had been published was 2.1±3.7. About two-thirds 
(354/497; 71%) of the reports had been cited less than 
five times or not at all.
Figure 1 Flow chart of the study selection process.
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Authorship affiliations: first authors of 354/497 (71%) 
reports were affiliated with Palestinian institutions, 29/497 
(6%) with a regional institution and 114/497 (23%) with 
an international institution. Out of the 497 coauthors, 
87 (18%) were affiliated with one Palestinian institution, 
149 (30%) with more than one Palestinian institution, 30 
(6%) with Palestinian and regional institutions and 231 
(47%) with different Palestinian and international insti-
tutions. The number of authors per report ranged from 
1 to 24. Most (361/497; 73%) of the reports were coau-
thored by four to six authors.
Study questions: three hundred and sixty (72%) of 
the reports presented prevalence/association studies, 
60/497 (12%) therapeutic studies, 25/497 (5%) aetiolog-
ical studies, 16/497 (3%) prognostic studies and 10/497 
(2%) diagnostic studies. Three-quarters (372/497; 75%) 
of the studies reported were cross-sectional surveys. Only 
16/497 (3.2%) were reports of controlled trials, and only 
4/497 (0.8%) were systematic reviews. Sources of funding 
were not mentioned in about two-thirds (341/497; 69%) 
of the reports. The most commonly reported sources of 
funding were international (107/497; 22%) and local 
(49/497; 10%). Table 1 provides information on the 
general characteristics of the reports.
Quality of reporting overall
We assessed about a third (155/497; 31%) of the reports 
as being adequate—at least 50% of all relevant items 
had been completely reported. However, no report had 
adequately covered all items. The median (first and third 
quantiles) percent of completely reported items per 
article was 36.4% (IQR 22.7%–54.6%), with a maximum 
of 95.5% of items completely reported in one article.
Completeness of reporting for the Introduction was 
generally high (68% of subitems per section), whereas 
title and abstract (40%), methods (32%), results (44%) 
and discussion (35% of subitems per section) were 
generally lower (see online supplementary figure S1). 
There was moderate inter-rater agreement between the 
two quality assessors (kappa statistics=0.52; 95% CI=0.46 
to 0.59).
reference to existing evidence
Of the 497 reports included, only 78 (15.7%) referred to 
systematic reviews of relevant existing evidence and the 
majority (419; 84.3%) did not cite at least one systematic 
review. Referring to systematic reviews or meta-analyses 
was associated with (i) collaboration among Palestinian 
and international institutions; (ii) studies of therapy/
treatment; (iii) RCTs; and (iv) recent publication. 
However, higher quality of reporting was not associated 
with citation of relevant systematic reviews or meta-anal-
yses (table 1).
Quality of reports of observational research
As the majority of the reports (439/497; 88%) were of 
studies of observational data, we assessed their quality using 
the STROBE checklist. Of the 439 observational studies 
assessed using STROBE, none completely addressed all 
22 STROBE checklist items nor was any checklist item 
completely addressed in all 439 reports. Figure 2 shows 
the proportion of items assessed completely, partially or 
not at all. Of the 439 reports, 307 (69.9%) explained the 
scientific background and rationale for conducting the 
research and 297 (67.7%) its specific objectives. However, 
only 11/439 reports (2.5%) provided adequate informa-
tion about eligibility criteria and sources and methods of 
selection of participants. Other items that were poorly 
reported were quantitative variables and how they were 
handled in the analyses (26/439; 5.9%); efforts to address 
potential sources of bias (35/439; 8%); sample size calcu-
lations (50/439; 11.4%); and funding sources (74/439; 
17%). Only 180/439 (41%) reports identified the study 
design in the title or abstract and provided an informa-
tive, balanced summary of the study with the number 
of individuals at each stage of the study and use of flow 
diagrams (171/439; 39%). Only 151/439 (34%) reports 
mentioned key elements of the study design early in the 
text.
The most frequent completely addressed item was 
reporting of outcome data, with 407/439 (93%) giving 
the number of outcome events or summary measures. 
Two hundred and ninety-five reports (67.2%) discussed 
key results in relation to study objectives (sources of 
the data and methods of assessment (measurement) 
(285/439; 64.9%), main results as unadjusted estimates 
and their precision (274/439; 62.4%) and settings, loca-
tions and relevant dates (267/439; 60.8%). Only 124/439 
(28%) reports of observational studies mentioned the 
limitations of the study.
Factors associated with quality of reporting
Table 1 shows factors associated with higher quality of 
reporting. These were (1) first author affiliated to an 
international institution (PR1.6; 95% CI 1.2 to 2.0); (2) 
collaboration among different Palestinian institutions as 
well as Palestinian and international institutions (PR 2.9; 
95% CI 1.7 to 5.0); (3) funding provided by interna-
tional/NGO sources (PR 1.9; 95% CI 1. to 2.5); (4) recent 
publication after 2005 (PR 3.9; 95% CI 1.8 to 8.5); (5) 
authored by four or more co-authors (PR 1.5; 95% CI 1.1 
to 2.1); and (6) published in a journal with an impact 
factor equal to or greater than 2 (PR 1.4; 95% CI 1.0 to 
1.8). Case reports/series (PR 0.4; 95% CI 0.1 to 1.0) and 
studies of therapy/treatment (PR 0.58; 95% CI 0.34 to 
0.97) were associated with lower quality of reporting.
dIscussIons
The majority of the reports in our study were inade-
quate as judged by international reporting guidelines, 
and we did not find any report that had reported all 
items. Outcome data (ie, number of outcome events or 
summary measures) were the most frequently satisfacto-
rily reported items. Less than half of the reports provided 
adequate titles and abstracts, which are sometimes are the 
group.bmj.com on June 11, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Albarqouni L, et al. BMJ Open 2017;7:e016455. doi:10.1136/bmjopen-2017-016455
Open Access
Table 1 Characteristics of included studies and the factors associated with adequate reporting of included studies (≥50% 
items were completely reported per article)
Factors Studies (n (%*))
Adequately 
reported studies 
(n (%†))‡
 Prevalence ratio 
(95% CI)
Percentage 
of completely 
reported items per 
article
(median
 (IQR))
Refer to 
systematic 
reviews (n (%†))
Total 497 (100) 155 (31.0) 36 (23–55) 78 (15.7)
Affiliation(s) of the first author
  Palestine 354 (71.2) 99 (28.0) Reference 36 (22–50) 48 (13.6)
  Regional 29 (5.80) 6 (20.7) 0.7 (0.4 to 1.5) 28 (23–46) 6 (20.7)
  International 114 (22.9) 50 (43.9) 1.6 (1.2 to 2.0) 46 (27–64) 24 (21.1)
Collaborations
  The same 
Palestinian 
institution
87 (17.5) 12 (13.8) Reference 23 (14–36) 9 (10.3)
  Different Palestinians 
institutions
149 (30.0) 43 (28.9) 2.1 (1.2 to 3.8) 36 (23–54) 15 (10.1)
  Palestinian and 
regional institutions
30 (6.00) 9 (30.0) 2.2 (1.0 to 4.6) 41 (23–50) 5 (16.7)
  Palestinian and 
international 
institutions
231 (46.5) 91 (39.4) 2.9 (1.7 to 5.0) 43 (27–59) 49 (21.2)
Type of the study question
  Prevalence/
association
360 (72.4) 125 (34.7) Reference 41 (23–55) 55 (15.3)
  Aetiology/risk 
factors
25 (5.0) 8 (32.0) 0.9 (0.5 to 1.7) 41 (36–54) 0 (0.00)
  Diagnosis 10 (2.0) 0 (0.00) – 20 (15–33) 3 (30.0)
  Therapeutic/
intervention
60 (12.1) 12 (20.0) 0.6 (0.3 to 0.97) 32 (18–41) 16 (26.7)
  Prognosis 16 (3.2) 7 (43.8) 1.3 (0.7 to 2.2) 46 (41–56) 1 (6.3.0)
  Others (case report) 26 (5.2) 3 (11.5) 0.3 (0.1 to 0.97) 35 (25–44) 3 (11.5)
Study design
  Cross-sectional 372 (74.8) 121 (32.5) Reference 36 (23–55) 60 (16.1)
  Systematic review 4 (0.8) 2 (50.0) 1.5 (0.6 to 4.1) 44 (33–57) 0 (0.00)
  RCTs 8 (1.6) 0 (0.00) – 20 (19–29) 4 (50.0)
  Non-RCTs 8 (1.6) 0 (0.00) – 18 (12–25) 2 (25.0)
  Cohort 36 (7.2) 15 (41.7) 1.3 (0.9 to 1.9) 46 (32–55) 7 (19.4)
  Case–control 43 (8.7) 14 (32.6) 1.0 (0.6 to 1.6) 46 (25–50) 2 (4.7.0)
  Case reports/series 26 (5.2) 3 (11.5) 0.4 (0.1 to 1.0) 35 (25–44) 3 (11.5)
Funding sources
  Not reported/unclear 341 (68.6) 87 (25.5) Reference 33 (23–50) 47 (13.8)
  Local 
(governmental/ 
industry/ 
institutional)
49 (9.90) 16 (32.7) 1.3 (0.8 to 2.0) 41 (23–55) 11 (22.4)
  International and 
NGOs
107 (21.5) 52 (48.6) 1.9 (1.5 to 2.5) 46 (30–66) 20 (18.7)
Reporting guidelines
  STROBE 439 (88.3) 150 (34.2) Reference 41 (23–55) 66 (15.0)
Continued
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only parts of a report to be read. Study objectives were not 
clearly specified in about a third of reports. Only 2.5% 
of the reports of observational studies reported eligibility 
criteria and selection procedures completely, informa-
tion which is essential in critical appraisal of reports.
Having international input, either in the form of first 
authorship, a collaboration, coauthorships or receiving 
funding from an international organisation are associ-
ated with higher quality of reporting. Research reports 
coauthored by four or more researchers were more likely 
to be of higher quality, as were reports published after 
2005, or in journals with an impact factor of 2 or more. 
We intend to repeat our survey in 2–3 years’ time covering 
the period from September 2015, to assess whether there 
has been improvement in the quality of reporting.
Recent studies evaluating the quality of reporting of 
published reports of research have often been restricted 
to reports of studies with a specific study design (eg, 
Factors Studies (n (%*))
Adequately 
reported studies 
(n (%†))‡
 Prevalence ratio 
(95% CI)
Percentage 
of completely 
reported items per 
article
(median
 (IQR))
Refer to 
systematic 
reviews (n (%†))
Total 497 (100) 155 (31.0) 36 (23–55) 78 (15.7)
  PRISMA 4 (0.80) 2 (50.0) 1.5 (0.54 to 3.9) 44 (33–57) 0 (0.00)
  CONSORT 16 (3.20) 0 (0.00) – 20 (12–28) 6 (37.5)
  CARE 26 (5.20) 3 (11.5) 0.3 (0.1 to 0.99) 35 (25–44) 3 (11.5)
  STARD 11 (2.20) 0 (0.00) – 20 (17–33) 3 (27.3)
  TRIPOD 1 (0.20) 0 (0.00) – 32 (32–32) 0 (0.00)
Publication year
  2005 68 (13.7) 6 (8.80) Reference 23 (14–36) 4 (5.90)
  2005–2010 164 (33.0) 49 (29.9) 3.4 (1.5 to 7.5) 36 (23–50) 22 (13.4)
  2010 265 (53.3) 100 (37.7) 4.3 (2.0 to 9.3) 41 (23–55) 52 (19.6)
Number of authors per article
  Single 51 (10.3) 7 (13.7) Reference 27 (18–36) 6 (11.8)
  2–3 134 (27.0) 36 (26.9) 2.0 (0.9 to 4.1) 36 (23–50) 14 (10.4)
  4–6 227 (45.7) 75 (33.0) 2.4 (1.2 to 4.9) 41 (23–55) 35 (15.4)
  7–10 57 (11.5) 23 (40.4) 2.9 (1.4 to 6.3) 46 (27–63) 15 (26.3)
  More than 10 28 (5.60) 14 (50.0) 3.6 (1.7 to 8.0) 48 (30–73) 8 (28.6)
Impact factor of the journal
  No impact factor 191 (38.4) 54 (28.3) Reference 36 (23–50) 29 (15.2)
  Less than 2 146 (29.4) 39 (26.7) 0.9 (0.7 to 1.3) 32 (18–50) 19 (13.0)
  2 or more 160 (32.2) 62 (38.8) 1.4 (1.0 to 1.8) 42 (31–59) 30 (18.8)
Number of citations per article
  None 164 (33.0) 46 (28.0) Reference 36 (23–51) 28 (17.1)
  Less than 5 190 (38.2) 59 (31.1) 1.1 (0.8 to 1.5) 36 (23–53) 34 (17.9)
  5 or more 143 (28.8) 50 (35.0) 1.3 (0.9 to 1.7) 41 (23–55) 16 (11.2)
Referred to previous relevant systematic reviews
  Yes 78 (15.7) 30 (38.5) Reference 44 (31–67) –
  No 419 (84.3) 125 (29.8) 1.3 (0.9 to 1.8) 36 (23–50) –
*The denominator of the percentage is the total included studies (n=497).
†The denominator of the percentage is the number of studies in each subgroup (row subgroup).
‡Adequately reported means≥50% items were completely reported per article.
Bold means significant (p value of Fisher’s exact test of statistical significance was <0.05).
CARE, CAse REport; CONSORT, CONsolidated Standards of Reporting Trials; NGO, non-governmental organisation; PRISMA, Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomised controlled trial; STARD, Standards for Reporting of Diagnostic 
Accuracy; STROBE, STrenghtening the Reporting of Observational studies in Epidemiology; TRIPOD, Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis.
Table 1 Continued 
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RCTs25), disease area (eg, dermatology26) or to reports 
published in a limited number of journals.27 Despite the 
considerable heterogeneity in the quality of reporting 
documented in these studies, they make clear that 
reporting quality is generally poor.28 29 A systematic 
review of 50 studies (including >16 000 individual RCTs) 
evaluated the association between journal endorsement 
of the CONSORT statement and reporting quality found 
that there had been a slight improvement in the quality 
of reporting over recent years, but that it remained inad-
equate.30 Similarly, a survey of 456 observational studies 
found that the quality of reporting increased over time 
but remained unsatisfactory.31
Our findings were also comparable to findings from 
other developing countries. In a systematic review of all 
published reports of RCTs in China in 2004 (n=307), the 
quality of reporting was generally poor and lagged behind 
the quality of reports of RCTs in the developed world.32 
Similarly, a survey of reports of medical research in Indo-
nesia found that only a small proportion of reports were 
of high quality.33
It is worth mentioning that our findings reflect what was 
reported and not what was actually done. It is important 
to note that poor reporting does not necessarily reflect 
methodologically inadequate studies, and that apparently 
flawless reporting is no guarantee that a study was well 
conducted, or indeed that it was not completely fabricated.
strengths and limitations
Strengths of our study included independent screening 
and data extraction from reports by two authors and 
our use of internationally developed criteria from the 
EQUATOR Network. One of its limitations is that we 
only searched two databases—Medline and Scopus—and 
that is only up to 2015 so we may have missed eligible 
studies not covered by these databases. In addition, only 
one author assessed reporting quality in all 497 included 
reports, although two authors independently assessed 
reporting quality in a 10% random sample of reports, 
with a moderate inter-rater agreement.
conclusions
The quality of Palestinian medical and health reports 
has been improving but remains well below a satisfactory 
level. The inadequate reporting we have documented 
is contributing to waste in research in Palestine, where 
resources for health research are very limited. As else-
where (www. rewardalliance. net), Palestine cannot afford 
waste in medical and health research. To judge by the 
reports we have studied, the Palestinian research insti-
tutions and researchers need to pay greater attention to 
ways of reducing waste and increasing value in research. 
International reporting guidelines should be endorsed 
and adopted by Palestinian institutions and academics, 
both to improve the reporting quality of research and to 
guarantee proper design and execution of research.
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